Core Viewpoint - Peijia Medical-B (09996) reported annual performance for the period ending December 31, 2025, with revenue approximately RMB 700 million to 720 million, reflecting a year-on-year growth of about 13.7% to 17.0% [1][3]. Group 1: Revenue Performance - The company achieved revenue of approximately RMB 700 million to 720 million during the reporting period [1][3]. - The year-on-year growth rate is estimated to be between 13.7% and 17.0% [1][3]. Group 2: Growth Drivers - The sustained revenue growth is primarily attributed to the strong performance of all three major product lines in the neurointerventional business [1][5]. - The market share in China's transcatheter aortic valve replacement (TAVR) sector continues to expand, driven mainly by the successful launch of the high-end TaurusMax® 3D adjustable TAVR system [1][5].
沛嘉医疗-B发布2025年度业绩 实现收入约7亿至7.2亿元同比增长约13.7至17.0%